Mangafodipir is a hepatocyte-specific contrast agent and an effective inhibitor of conditions caused by CIPN (chemotherapy-induced peripheral neuropathy) and other oxidative stress pathways. It does not negatively impact the tumor-killing efficacy of chemotherapy.